Navigation Links
Ovarian transplantation: New technique gives greatly improved results in this delicate operation
Date:6/29/2009

Amsterdam, The Netherlands: Ultra-fast freezing of ovarian tissue from women who have lost their fertility as a result of cancer treatment can lead to it being used in transplants with the same success rate as fresh tissue, a researcher told the 25th annual conference of the European Society of Human Reproduction and Embryology today (Monday 29 June). Dr. Sherman Silber, Director of the St. Louis Infertility Centre, St. Louis, Missouri, USA, said that freezing tissue by the vitrification method, which avoids ice formation, meant that oocyte (egg) viability was almost identical with that seen in fresh oocytes.

Dr. Silber and colleagues used standard viability testing with fluorescent microscopy to determine the loss or preservation of oocytes in fresh and frozen ovarian tissue of 15 young women undergoing cancer treatment. They also followed up nine homozygotic twin patients after fresh ovary transplantation for the duration of ovarian function and pregnancy outcome, and tested spare tissue that had also been frozen from their ovaries at the time of transplant. Tissue was preserved either by rapid cooling vitrification or by classical slow freezing methods.

"We found that 91.9% of the fresh oocytes were viable compared with 88.9% of those vitrified. However, slow freezing resulted in a 56% loss of viability", said Dr. Silber.

Transplantation of the tissue resulted in a duration of ovarian function of more than four years in five of the seven cases followed up for that long, and all patients regained a normal ovarian cycle within four to five months after the transplant. There was no difference in terms of pregnancy or ovulatory menstrual cycling between fresh and frozen grafts. The scientists used the cortical grafting technique, where very thin slices of tissue are transplanted. This technique is much easier to perform than the delicate microvascular technique, which they described last year in an effort to prevent egg loss and to le
'/>"/>

Contact: MaryRice
mary@mrccommunication.org
European Society for Human Reproduction and Embryology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
2. Promising new treatment option for women with recurrent ovarian cancer
3. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
4. Oocyte-specific gene mutations cause premature ovarian failure
5. Ovarian cancer stem cells identified, characterized
6. Mutation of the COX2 gene can double or treble a womans risk of ovarian cancer
7. Colon cancer screening technique shows continued promise in new study
8. Beating heart machine expedites research and development of new surgical tools, techniques
9. New genomic technique uncovers coral transcriptome
10. Lyncean Technologies Inc. receives $1.2 M from NCRR to develop new imaging technique
11. Indigenous peoples at world summit to share climate change observations, coping techniques
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Shenzhen, China The Asian Cancer Research Group ... and Company, Merck (known as MSD outside the ... with BGIthe world,s largest genomics organizationtoday announced the ... of recurrent hepatitis B virus (HBV) integration in ...
... researchers have known for well over a century that different ... one has been able to determine the mechanisms of organ ... New details that could help shed light on this hypothesis ... Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, ...
... new study, children exposed to high levels of the ... chromosomal aberrations (CAs), which have been previously associated with ... and long-lasting subtype of CAs. Researchers from the ... Mailman School of Public Health, Columbia University Medical Center, ...
Cached Biology News:ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration 2ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration 3Cancerous tumors deliver pro-metastatic information in secreted vesicles 2Cancerous tumors deliver pro-metastatic information in secreted vesicles 3Cancerous tumors deliver pro-metastatic information in secreted vesicles 4Children exposed to the common pollutant naphthalene show signs of chromosomal damage 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 3
(Date:3/6/2015)... , March 6, 2015 ...   2011 von der Assistance Publique - ... initiiert., Sie ist eine französische, gemeinschaftliche, randomisierte ... Patienten rekrutiert wurden. Verglichen werden Patienten mit ... Yttrium-90 Harz-Mikrosphären oder Sorafenib behandelt wurden. Die ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... veterans to be able to get an Advanced Semen ... money, stress, blaming and guessing are all risk factors ... assuming the woman is the source of the infertility. ... female. LifeCell Dx has the simplest, least complicated ...
(Date:3/5/2015)... Park, NC (PRWEB) March 05, 2015 ... announced that Pierre Noel, M.D., Professor of Medicine, ... to the Company’s Board of Directors. ... “We are extremely fortunate to have Dr. Noel, ... country’s leading healthcare organization, join Entegrion’s Board. His ...
(Date:3/5/2015)... -- In response to the incorrect assertions by LD, distributed ... on February 12, 2015. Impeto Medical SAS and its ... their SUDOSCAN® devices have been proven to provide accurate ... have the courts decide this dispute rather than the ... written by Key Opinion Leaders, published by significant peer-reviewed ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2
... 13 Proteon,Therapeutics, Inc. ( http://www.proteontherapeutics.com ), announced ... the European Patent Office. The patent,(No. 1220830) covers ... as elastases for,dilating arteries and veins in humans. ... in June and December of 2006. Proteon Therapeutics,owns ...
... has received its second Frost & Sullivan Technology Award ... the Frost & Sullivan Awards Banquet,Signalife was awarded the ... Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, and its ... accept the award., Signalife, Inc. is in a ...
... Advancing Lead Candidate HspE7 into Phase 2 Clinical Trial in ... ... 13 Nventa Biopharmaceuticals,Corporation announced today financial results for the year ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO ), During 2007, the Company achieved ...
Cached Biology Technology:Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins 2Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7
... dihydrochloride) is a fluorescent counterstain ... in color. The bright blue ... red fluorochromes such as rhodamine, ... DAPI can be used for ...
... sets of glass plates, bar clamp, and ... features of these units are:, safety interlock ... reservoirs , upper and lower reservoirs have ... safe disposal of buffer solutions , leveling ...
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: